Skip to main content
Equibles
BHC logo

BHC · Bausch Health Companies Inc. · Metrics

Track BHC — free

Use BHC with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BHC.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$6.07 -0.09 (-1.46%) At close · Sep 10
Rebalance outlook locked
Market Cap
$2.26B
Shares
373.99M

BHC metrics

80 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$6.07
Market cap
$2.26B

Price action

20 metrics
Price change (1W)
-9.8%
Price change (30D)
-1.3%
Price change (3M)
+19.6%
Price change (6M)
+13.4%
Price change (YTD)
-11.4%
Price change (1Y)
-14.6%
Trailing year
Price change (5Y)
-78.5%
52-week high
$7.90
52-week low
$4.43
Change from 52-week high
-22.0%
Change from 52-week low
+39.1%
Annualized volatility
56.4%
Annualized volatility (3M)
81.3%
Beta
1.0
RSI (14D)
47.0
Price vs SMA 50
+7.1%
Price vs SMA 200
+5.2%
Avg volume (3M)
3.56M
Relative volume
0.4
Average dollar volume
$20.95M

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
373.99M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
2.0×
reciprocal yield 51.3%
EV / EBITDA
10.3×
reciprocal yield 9.7%
EV / EBIT
24.0×
reciprocal yield 4.2%
P / sales
0.2×
reciprocal yield 480.5%
P / book
—
FCF yield
63.3%
TTM · current market cap
Buyback yield
—
P / FCF
1.6
reciprocal yield 63.3%
P / operating cash flow
1.3
reciprocal yield 79.7%
Earnings yield
-48.6%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
18.1×
reciprocal yield 5.5%
EV / revenue historical average (3Y)
2.4×
reciprocal yield 41.2%
EV / revenue historical average (5Y)
2.7×
reciprocal yield 36.9%
EV / EBIT historical average (3Y)
24.8×
reciprocal yield 4.0%
EV / EBIT historical average (5Y)
48.4×
reciprocal yield 2.1%
EV / EBITDA historical average (3Y)
10.2×
reciprocal yield 9.8%
EV / EBITDA historical average (5Y)
11.3×
reciprocal yield 8.9%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-07-29

Profitability

9 metrics
Gross margin
—
Operating margin
8.1%
Trailing 12 months
Net margin
-10.1%
Gross profit (TTM)
—
Operating profit (TTM)
$883.00M
Net income (TTM)
−$1.10B
Trailing 12 months
Diluted EPS (TTM)
$-2.96
FCF margin
13.2%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-1.50

Growth

11 metrics
Revenue growth YoY
+12.7%
Year over year
Net income growth YoY
+74.3%
Revenue (TTM)
$10.85B
Trailing 12 months
EPS growth YoY
+70.0%
Shares change YoY
+1.3%
Year over year · more shares
Revenue CAGR (3Y)
+8.1%
Revenue CAGR (5Y)
+5.0%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
+4.4%

Quality

14 metrics
Return on equity
—
Return on assets
-4.4%
Debt / equity
—
Current ratio
1.4
EBITDA (TTM)
$2.06B
Free cash flow (TTM)
$1.43B
Quick ratio
1.1
Interest coverage
—
Net debt / EBITDA
9.2
Return on invested capital
—
Trailing 12 months
Net cash
−$18.92B
Latest balance sheet
Cash & equivalents
$1.82B
Total assets
$24.79B
Total debt
$20.74B

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$1.80B
Capital expenditures (TTM)
$369.00M
R&D (TTM)
$663.00M
SG&A (TTM)
$3.44B
Stock compensation (TTM)
$233.00M
R&D / revenue
6.1%
Stock compensation / revenue
2.1%

Ownership (13F)

3 metrics
13F filers
224
13F filer change QoQ
-8
Institutional ownership
66.9%

Short interest

3 metrics
Short interest
2.2%
Latest settlement · 3.0 days to cover
Days to cover
3.0d
Short-squeeze score
61 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$258,894
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 885590 CUSIP 071734107 13F (30d) 126 filings 124 filers Visit website Investor relations